|
[1]
|
Dalbeth, N., Merriman, T.R. and Stamp, L.K. (2016) Gout. Lancet, 388, 2039-2052. [Google Scholar] [CrossRef]
|
|
[2]
|
高尿酸血症相关疾病诊疗多学科共识专家组. 中国高尿酸血症相关疾病诊疗多学科专家共识[J]. 中华内科杂志, 2017, 56(3): 235-248.
|
|
[3]
|
Richette, P. and Bardin, T. (2010) Gout. The Lancet, 37, 318-328. [Google Scholar] [CrossRef]
|
|
[4]
|
中华医学会风湿病学分会. 原发性痛风诊断和治疗指南[J]. 中华风湿病学杂志, 2011, 15(6): 410-413.
|
|
[5]
|
Lee, S.J., Hirsch, J.D., Terkeltaub, R., Khanna, D., Singh, J.A., Sarkin, A., et al. (2009) Perceptions of Disease and Health-Related Quality of Life among Patients with Gout. Rheumatology, 48, 582-586. [Google Scholar] [CrossRef] [PubMed]
|
|
[6]
|
Schneider, H.-G. and Lam, Q.T. (2007) Procalcitonin for the Clinical Laboratory: A Review. Pathology, 39, 383-390. [Google Scholar] [CrossRef] [PubMed]
|
|
[7]
|
Maruna, P., Nedelnikova, K. and Gurlich, R. (2000) Physiology and Genetics of Procalcitonin. Physiological Research, 49, S57-S61.
|
|
[8]
|
Wacker, C., Prkno, A., Brunkhorst, F.M. and Schlattmann, P. (2013) Procalcitonin as a Diagnostic Marker for Sepsis: A Systematic Review and Meta-Analysis. The Lancet Infectious Diseases, 13, 426-435. [Google Scholar] [CrossRef]
|
|
[9]
|
宇世飞, 李芳秋. 降钙素原的临床应用进展[J]. 医学研究生学报, 2016, 29(2): 206-209.
|
|
[10]
|
Ilaria, S., Laurent, A., Alexis, M., Hausfater, P. and Amoura, Z. (2014) Can procalcitonin Be Used to Distinguish between Disease Flare and Infection in Patients with Systemic Lupus Erythematosus: A Systematic Literature Review. Clinical Rheumatology, 33, 1209-1215. [Google Scholar] [CrossRef] [PubMed]
|
|
[11]
|
Cem, G. and Irving, K. (1999) Acute-Phase Proteins and Other Systemic Responses to Inflammation. The New England Journal of Medicine, 340, 448-454. [Google Scholar] [CrossRef]
|
|
[12]
|
Meisner, M. (2002) Pathobiochemistry and Clinical Use of Procalcitonin. Clinica Chimica Acta, 323, 17-29. [Google Scholar] [CrossRef]
|
|
[13]
|
Simon, L., Gauvin, F., Amre, D.K., Saint-Louis, P. and Lacroix, J. (2004) Serum Procalcitonin and C-Reactive Protein Levels as Markers of Bacterial Infection: A Systematic Review and Meta-Analysis. Clinical Infectious Diseases, 39, 206-217. [Google Scholar] [CrossRef] [PubMed]
|
|
[14]
|
Uzzan, B., Cohen, R., Nicolas, P., Cucherat, M. and Perret, G.-Y. (2006) Procalcitonin as a Diagnostic Test for Sepsis in Critically Ill Adults and after Surgery or Trauma: A Systematic Review and Meta-Analysis. Critical Care Medicine, 34, 1996-2003. [Google Scholar] [CrossRef]
|
|
[15]
|
Raúl, B.B. and Heriberto, A.C. (2012) Procalcitonin for the Diagnosis of Late Onset Sepsis in Newborns of Very Low Birth Weight. Revista chilena de infectologia, 29, 511-516.
|
|
[16]
|
Dandona, P., Nix, D., Wilson, M.F., Aljada, A., Love, J., Assicot, M., et al. (1994) Procalcitonin Increase after Endotoxin Injection in Normal Subjects. The Journal of Clinical Endocrinology and Metabolism, 79, 1605-1608.
|
|
[17]
|
Wen, L., Raj, S.K., Ying, W., Su, Q., Huang, Y., Zhang, Y.L., et al. (2015) High Level Serum Procalcitonin Associated Gouty Arthritis Susceptibility: From a Southern Chinese Han Population. PLoS ONE, 10, e0132855. [Google Scholar] [CrossRef] [PubMed]
|
|
[18]
|
Muhammad, S.M., Etienne, H.L. and van Laar, J.M. (2015) Is Serum Procalcitonin Measurement a Useful Addition to a Rheumatologist’S Repertoire? A Review of Its Diagnostic Role in Systemic Inflammatory Diseases and Joint Infections. Rheumatology, 54, 231-240. [Google Scholar] [CrossRef] [PubMed]
|
|
[19]
|
Brunkhorst, R., Eberhardt, O.K., Haubitz, M. and Brunkhorst, F.M. (2000) Procalcitonin for Discrimination between Activity of Systemic Autoimmune Disease and Systemic Bacterial Infection. Intensive Care Medicine, 26, S199-S201. [Google Scholar] [CrossRef]
|
|
[20]
|
Eberhard, O.K., Haubitz, M., Brunkhorst, F.M., Kliem, V., Koch, K.M. and Brunkhorst, R. (1997) Usefulness of Procalcitonin for Differentiation between Activity of Systemic Autoimmune Disease (Systemic Lupus Erythematosus/Systemic Antineutrophil Cytoplasmic Antibody‐Associated Vasculitis) and Invasive Bacterial Infection. Arthritis & Rheumatism, 40, 1250-1256.
|
|
[21]
|
Lioté, F. and Ea, H.-K. (2006) Gout: Update on Some Pathogenic and Clinical Aspects. Rheumatic Disease Clinics of North America, 32, 295-311. [Google Scholar] [CrossRef] [PubMed]
|
|
[22]
|
Virginie, P. and Fabio, M. (2007) The Inflammasome, Autoinflammatory Diseases, and Gout. Joint Bone Spine, 74, 571-576. [Google Scholar] [CrossRef] [PubMed]
|
|
[23]
|
Tae, C.S. and Soo, S.J. (2016) Serum Procalcitonin as a Useful Serologic Marker for Differential Diagnosis between Acute Gouty Attack and Bacterial Infection. Yonsei Medical Journal, 57, 139-144. [Google Scholar] [CrossRef] [PubMed]
|
|
[24]
|
吕颖, 张永超. 血清降钙素原水平在鉴别慢性痛风急性发作和细菌感染中的价值[J]. 安徽医药, 2017, 21(3): 481-484.
|
|
[25]
|
Irina, B., Yood, R.A. and Hassan, I. (2010) Serum Procalcitonin in Systemic Autoimmune Diseases—Where Are We Now? Seminars in Arthritis and Rheumatism, 40, 176-183. [Google Scholar] [CrossRef] [PubMed]
|
|
[26]
|
Schmidt, J., Duhaut, P., Bourgeois, A.M., Salle, V., Smail, A., Chatelain, D., et al. (2009) Procalcitonin at the Onset of Giant Cell Arteritis and polymyalgia Rheumatica: the GRACG Prospective Study. Rheumatology, 48, 158-159. [Google Scholar] [CrossRef] [PubMed]
|